News – Page 1112 – Endpoints News

Star team quietly raises $21M to launch the latest immuno-oncology startup Torque

8 years ago

BioMarin says the FDA game clock now ticking on their blockbuster hopeful pegvaliase

8 years ago

Otonomy staggered by an ugly PhIII failure for lead pipeline drug

8 years ago

In stunning about-face, FDA invites Eli Lilly to quickly refile blockbuster hopeful baricitinib

8 years ago

Medicines Co scores FDA OK for new antibiotic, now up on the auction block

8 years ago

A nonprofit group’s Chagas drug beat out Martin Shkreli's old rival to FDA OK, valuable PRV

8 years ago

Celgene antes up $195M more to stay close to Forma, adding neurodegeneration focus

8 years ago

Celgene, Google double down on Armo’s PhIII immuno-oncology drug with $67M round

8 years ago

Daiichi Sankyo gets a “breakthrough” at the FDA; InVivo restructures, cuts jobs

8 years ago

Seven years in the making, Seattle Genetics picks up early option on Genmab's ADC effort

8 years ago

FDA derails Acorda's marketing pitch, creating a crisis as flagship drug founders

8 years ago

Jazz gambles $175M on a triple-pronged armed antibody pact with ImmunoGen

8 years ago

AstraZeneca auctions off rights to another pipeline drug as Takeda grabs $400M Parkinson's deal

8 years ago

Merck hits a bloop single in an epic PhIII CETP cardio contest. Now what?

8 years ago

Bayer, J&J eye blockbuster supplemental OK for Xarelto; SetPoint raises $30M for bioelectronics

8 years ago

Viking leads a $46M raise for a struggling aTyr Pharma

8 years ago

Aveo takes a big step forward as comeback plan delivers EU OK for tivo

8 years ago

CSL snags a preclinical stem cell therapy in $416M Calimmune buyout, plans to spin out HIV effort

8 years ago

Diving deep into CAR-T, Gilead forges $12B buyout deal for Kite Pharma

8 years ago

Novartis team scores a pioneering first in cardio R&D. But can they sell it?

8 years ago

Novartis recruits a global digital chief; Shire CFO jumps ship

8 years ago

Novartis’ Kisqali to go head-to-head with Pfizer’s Ibrance; USC joins regional biotech alliance

8 years ago

After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine

8 years ago

Novartis returns to the discount aisle, buys Xoma's failed PhIII drug for $31M

8 years ago

First page Previous page 1109 1110 111111121113 1114 1115 Next page Last page